Schering contrast agent debuts in Sweden:
This article was originally published in Clinica
Executive Summary
Schering (Berlin, Germany) has gained approval for its liver specific-contrast agent, Resovist, in Sweden. Schering used the EU's mutual recognition procedure to gain the approval, which marks the worldwide marketing debut of the product. Resovist was developed in collaboration with Japan's Meito Sangyo. It will be launched in Sweden in mid-2001. The agent is injected as an intravenous bolus and can detect and characterise small liver focal lesions, enabling early detection of hepatic carcinoma or metastases. Imaging is immediate, cutting down examination time. Schering claims a 60 % share of world MRI contrast agent sales.